Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life study
View ORCID ProfileIvan Gentile, Riccardo Scotto, View ORCID ProfileNicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico II COVID team
doi: https://doi.org/10.1101/2022.08.23.22278585
Ivan Gentile
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Riccardo Scotto
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Nicola Schiano Moriello
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Biagio Pinchera
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Riccardo Villari
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Emilia Trucillo
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Luigi Ametrano
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Ludovica Fusco
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Giuseppe Castaldo
2Department of Molecular Medicine and Medical Biotechnologies - University of Naples Federico II – Naples Italy
3CEINGE - Advanced Biotechnologies - Naples Italy
Antonio Riccardo Buonomo
1Department of Clinical medicine and Surgery - University of Naples Federico II – Naples Italy
Article usage
Posted August 25, 2022.
Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life study
Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico II COVID team
medRxiv 2022.08.23.22278585; doi: https://doi.org/10.1101/2022.08.23.22278585
Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life study
Ivan Gentile, Riccardo Scotto, Nicola Schiano Moriello, Biagio Pinchera, Riccardo Villari, Emilia Trucillo, Luigi Ametrano, Ludovica Fusco, Giuseppe Castaldo, Antonio Riccardo Buonomo, Federico II COVID team
medRxiv 2022.08.23.22278585; doi: https://doi.org/10.1101/2022.08.23.22278585
Subject Area
Subject Areas
- Addiction Medicine (395)
- Allergy and Immunology (707)
- Anesthesia (198)
- Cardiovascular Medicine (2904)
- Dermatology (249)
- Emergency Medicine (435)
- Epidemiology (12667)
- Forensic Medicine (10)
- Gastroenterology (820)
- Genetic and Genomic Medicine (4524)
- Geriatric Medicine (411)
- Health Economics (722)
- Health Informatics (2890)
- Health Policy (1062)
- Hematology (382)
- HIV/AIDS (917)
- Medical Education (421)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4283)
- Nursing (232)
- Nutrition (630)
- Oncology (2245)
- Ophthalmology (639)
- Orthopedics (257)
- Otolaryngology (324)
- Pain Medicine (274)
- Palliative Medicine (83)
- Pathology (492)
- Pediatrics (1188)
- Primary Care Research (491)
- Public and Global Health (6870)
- Radiology and Imaging (1510)
- Respiratory Medicine (912)
- Rheumatology (433)
- Sports Medicine (380)
- Surgery (480)
- Toxicology (60)
- Transplantation (207)
- Urology (177)